Key result
Beraprost sodium (40 or 60 micrograms) decreased platelet aggregation between 0.5 and 1 hour after dosing, with a terminal half-life ranging from 0.50 to 0.91 hours.
Why the study?
Does oral beraprost sodium inhibit platelet aggregation in healthy volunteers?
RCT (n=12)
Double-blind
Randomized
Does oral beraprost sodium inhibit platelet aggregation in healthy volunteers?
Answers are grounded in this paper and cite their sources.
Beraprost sodium at doses of 40 or 60 micrograms exerts maximal antiaggregating effects between 0.5 and 1 hour after oral administration in healthy volunteers.
Beraprost sodium (BPS) is an orally stable analogue of prostacyclin that inhibits adenylate-cyclase-dependent platelet aggregation and is proposed for treatment of chronic arterial occlusion. To determine the duration and intensity of platelet antiaggregation with BPS, 12 healthy, nonsmoking, male white volunteers participated in a double-blind, dose-escalating design with randomized placebo, placebo-controlled, cross-over study. After overnight fasting, single (20, 40, 60 micrograms and placebo) and repeated [20, 40, 60 micrograms and placebo) and repeated [20, 40, 60 micrograms and placebo three times daily (t.i.d.) for 3 days] oral doses of BPS were administered. Mean percentage of inhibition of ADP-induced aggregation normalized to placebo was measured for 8 h after drug administration and related to plasma concentrations (Cp) of the active enantiomer (APS 314d). BPS 40 and 60 micrograms decreased platelet aggregation 1 h after single doses, and 0.5 h and 1 h after repeated doses. BPS 20 micrograms had no significant effect. APS 314d pharmacokinetics was linear, and its terminal half-life (t 1/2) ranged from 0.50 +/- 0.21 to 0.91 +/- 0.27 h (mean +/- SD) independently of BPS dose. Antiaggregating effects were poorly related to Cp of APS 314d (r2 < or = 0.2). Some subjects complained of moderate postdrug absorption headaches (7 of 12 after single and 8 of 12 after repeated doses) and flushes (6 of 12 and 7 of 12, respectively). These data indicate that orally active prostacyclin BPS (40 or 60 micrograms) exerts its maximal antiaggregating effects between 0.5 and 1 h.
No takes yet. Share an insight, caveat, or question.
Démolis et al. (1993) conducted an RCT in Healthy volunteers (n=12). Beraprost sodium (BPS) vs. Placebo was evaluated on Mean percentage of inhibition of ADP-induced aggregation normalized to placebo. Beraprost sodium (40 or 60 micrograms) decreased platelet aggregation between 0.5 and 1 hour after dosing, with a terminal half-life ranging from 0.50 to 0.91 hours.
Synapse has enriched 10 related papers. Consider them for comparative context: